Attending the Municipal People's Congress Meeting
Release time:
2020-07-22
to participate in the Municipal People's Congress meeting feeling
originally scheduled for 2# in early June Jinhua City "two sessions", due to the impact of the epidemic postponed to the end of 4# August, I as a representative of Jinhua City People's Congress, in this special period to participate in the meeting, a lot of feelings.
bright code" and wear disposable medical surgical masks. At the
2019 government work report. many indexes mentioned in the report are the first in the whole province and the country. the Jinhua experience formed has been popularized in the whole province and even the whole country, and the achievements are obvious to all, exciting, inspiring and warm. By the sudden outbreak, the global economy is facing greater downward pressure, the General Assembly Mayor Yin focused on the government and enterprises to work together to overcome the difficulties, the government to greater efforts to reduce taxes and fees, rent and interest reduction. We will implement policies such as loan extension, non-repayment of principal and renewal of loans, and reduction and exemption of "two taxes" on housing and land. We will reduce the social security expenses of enterprises in stages, continuously reduce the cost of electricity, water and gas for enterprises, and reduce the burden of enterprises by more than 200 billion yuan. The introduction of greater efforts to stabilize foreign trade policies, to carry out "gold trade and credit integration" business, to increase credit insurance subsidies, to encourage enterprises to participate in online exhibitions, to support enterprises to export to domestic sales.
" strategy; on the one hand, reduce relatively backward industries, on the other hand, cultivate and expand advanced production capacity, promote sustained and healthy economic development through the growth and decline of industries, and increase the proportion of advanced manufacturing and strategic emerging industries in the economic structure.
In 2020 , the sudden outbreak of the new coronary pneumonia epidemic affected the hearts of hundreds of millions of people across the country. As a researcher engaged in the health industry, I will also make full use of the advantages of peak health research to help the front line of epidemic prevention and control, and plan to develop a series of functional foods. The project mainly takes improving the body's immunity as the starting point and combines various prescriptions for treating "epidemic poison" in traditional Chinese medicine, modern cell screening technology is used to refine and improve the formula, and modern preparation technology is used to concentrate the active ingredients to make a series of functional foods with disease prevention and control efficacy and controllable quality. At the same time, I will further improve my own quality, strengthen the study of the party's principles and policies, enhance the ability to look at, think about and analyze problems, and ensure that all suggestions meet the requirements of high standing, clear views and solid content; work hard and devote myself to the construction of the enterprise to contribute to the healthy and rapid development of the enterprise. Deputies to the National people's Congress are not only an honor, but also a responsibility. In my future tenure, I will continue to bear in mind my mission and perform my duties for the people. to make greater contributions to further promoting the construction of economic and political civilization and a harmonious society in Jinhua. (Lu Guosheng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31